Compare BKU & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | CPRX |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2010 | 2006 |
| Metric | BKU | CPRX |
|---|---|---|
| Price | $48.57 | $31.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $51.58 | $35.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 14.61 | ★ 28.24 |
| EPS | ★ 0.83 | 0.50 |
| Revenue | $21,732,000.00 | ★ $119,072,803.00 |
| Revenue This Year | $16.26 | $9.20 |
| Revenue Next Year | $4.78 | $10.51 |
| P/E Ratio | ★ $58.51 | $62.94 |
| Revenue Growth | 7.45 | ★ 16.39 |
| 52 Week Low | $34.79 | $19.05 |
| 52 Week High | $52.11 | $32.56 |
| Indicator | BKU | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 70.75 |
| Support Level | $44.53 | $31.25 |
| Resistance Level | $49.02 | $32.56 |
| Average True Range (ATR) | 1.31 | 0.04 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 47.17 | 75.00 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.